Lauren Acevedo Molina, MD
Infectious Disease · San Juan, PRNPI 1316333669
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 24.3% of the total. 2025 is the largest year on record at $600, more than ten times the $38 reported in 2020.
Across 82 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$419
- Gilead$382
- Insmed, Inc.$233
- Melinta Therapeutics, LLC$161
- Viiv Healthcare Company$137
- Merck$135
- plus $257 from 4 others
Across 2 payments — averaging $12,750 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$26K
What the payments were for
- Food & beverage$1,70899%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $419 |
| Gilead | 15 | $382 |
| Insmed, Inc. | 11 | $233 |
| Melinta Therapeutics, LLC | 6 | $161 |
| Viiv Healthcare Company | 7 | $137 |
| Merck | 6 | $135 |
| Paratek Pharmaceuticals, Inc. | 5 | $117 |
| Johnson & Johnson | 4 | $74 |
| Aimmune Therapeutics, Inc. | 2 | $47 |
| Theratechnologies Inc. | 1 | $19 |
How this compares
$1,724 in reported general payments places this provider in the 70th percentile of 127 infectious disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 58 | $228,222 |
| JulucaDolutegravir/Rilpivirine | 11 | $41,357 |
| Daptomycin | 20 | $34,822 |
| Cefepime Hcl | 21 | $4,919 |
| MicafunginMicafungin Sodium | 14 | $3,287 |
| CeftriaxoneCeftriaxone Sodium | 35 | $2,181 |
| Cephalexin | 18 | $1,166 |
| Levofloxacin | 19 | $1,094 |
| Doxycycline Hyclate | 36 | $927 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $698 |
| Doxycycline Monohydrate | 11 | $593 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 35 | $398 |
| Fluconazole | 13 | $165 |
| Metronidazole | 11 | $150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $382 | $228,22258 claims |
| Viiv Healthcare CompanyJuluca | $137 | $41,35711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 127 infectious disease providers in Puerto Rico.
Other infectious disease in San Juan
- Vanessa Olivo EchavarrySan Juan$41K
- Angeles Rodriguez RosaSan Juan$27K
- Miguel Colon PerezSan Juan$12K
- Javier MoralesSan Juan$9K
- Mario LopezSan Juan$9K
- Armando Torres NievesSan Juan$4K
- Carmelo Santana-LopezSan Juan$4K
- Elba Arroyo CamunasSan Juan$3K
- Jonathan Ruiz GarciaSan Juan$3K
- Sandra Maldonado-RiveraSan Juan$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.